Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 402

1.

Dactylitis in entheropatic spondyloarthritis.

Peluso R, Costa L, Caso F, Del Puente A, Di Minno MN, Manguso F, Castiglione F, Scarpa R.

Clin Exp Rheumatol. 2016 Apr 15. [Epub ahead of print]

PMID:
27087311
2.

Mud-bath therapy and oral glucosamine sulfate in patients with knee osteoarthritis: a randomized, controlled, crossover study.

Peluso R, Caso F, Costa L, Sorbo D, Carraturo N, Di Minno MN, Carraturo F, Oriente A, Balestrieri U, Minicucci A, Del Puente A, Scarpa R.

Clin Exp Rheumatol. 2016 Apr 6. [Epub ahead of print]

PMID:
27050908
3.

Accelerated bone turnover identifies hemiplegic patients at higher risk of demineralization.

Del Puente A, Pappone N, Servodio Iammarrone C, Esposito A, Scarpa R, Costa L, Caso F, Bardoscia A, Del Puente A.

J Biol Regul Homeost Agents. 2016 Jan-Mar;30(1):291-6.

PMID:
27049105
4.

Impact of 24 months of anti-TNF therapy versus methotrexate on body weight in patients with rheumatoid arthritis: a prospective observational study.

Sfriso P, Caso F, Filardo GS, Botsios C, Costa L, Scarpa R, Todesco S, Spinella P, Oliviero F, Punzi L.

Clin Rheumatol. 2016 Apr 6. [Epub ahead of print]

PMID:
27048267
5.

Patient-reported impact of spondyloarthritis on work disability and working life: the ATLANTIS survey.

Ramonda R, Marchesoni A, Carletto A, Bianchi G, Cutolo M, Ferraccioli G, Fusaro E, De Vita S, Galeazzi M, Gerli R, Matucci-Cerinic M, Minisola G, Montecucco C, Pellerito R, Salaffi F, Paolazzi G, Sarzi-Puttini P, Scarpa R, Bagnato G, Triolo G, Valesini G, Punzi L, Olivieri I; ATLANTIS study group.

Arthritis Res Ther. 2016 Apr 1;18(1):78. doi: 10.1186/s13075-016-0977-2.

6.

[-2]proPSA versus ultrasensitive PSA fluctuations over time in the first year from radical prostatectomy, in an high-risk prostate cancer population: A first report.

De Luca S, Passera R, Sottile A, Fiori C, Scarpa RM, Porpiglia F.

BMC Urol. 2016 Mar 24;16(1):14. doi: 10.1186/s12894-016-0131-0.

7.

Influenza vaccine with adjuvant on disease activity in psoriatic arthritis patients under anti-TNF-α therapy.

Caso F, Ramonda R, Del Puente A, Darda MA, Cantarini L, Peluso R, Esposito C, Ortolan A, Fiocco U, Punzi L, Scarpa R, Costa L.

Clin Exp Rheumatol. 2016 Mar 11. [Epub ahead of print]

PMID:
26967009
8.

Emerging drugs for psoriatic arthritis.

Caso F, Del Puente A, Peluso R, Caso P, Girolimetto N, Del Puente A, Scarpa R, Costa L.

Expert Opin Emerg Drugs. 2016 Mar;21(1):69-79. doi: 10.1517/14728214.2016.1146679. Epub 2016 Feb 15.

PMID:
26807876
9.
10.

Does nephrectomy during radical adrenalectomy for stage II adrenocortical cancer affect patient outcome?

Porpiglia F, Fiori C, Daffara FC, Zaggia B, Ardito A, Scarpa RM, Papotti M, Berruti A, Scagliotti GV, Terzolo M.

J Endocrinol Invest. 2016 Apr;39(4):465-71. doi: 10.1007/s40618-015-0422-4. Epub 2015 Dec 22.

PMID:
26694705
11.

Long-term costs and outcomes in psoriatic arthritis patients not responding to conventional therapy treated with tumour necrosis factor inhibitors: the extension of the Psoriatic Arthritis Cost Evaluation (PACE) study.

Olivieri I, Cortesi PA, de Portu S, Salvarani C, Cauli A, Lubrano E, Spadaro A, Cantini F, Ciampichini R, Cutro MS, Mathieu A, Matucci-Cerinic M, Punzi L, Scarpa R, Mantovani LG; PACE Working Group.

Clin Exp Rheumatol. 2016 Jan-Feb;34(1):68-75. Epub 2015 Dec 3.

PMID:
26633622
12.

Pharmacological treatment of spondyloarthritis: exploring the effectiveness of nonsteroidal anti-inflammatory drugs, traditional disease-modifying antirheumatic drugs and biological therapies.

Caso F, Costa L, Del Puente A, Di Minno MN, Lupoli G, Scarpa R, Peluso R.

Ther Adv Chronic Dis. 2015 Nov;6(6):328-38. doi: 10.1177/2040622315608647. Review.

13.

Progress in understanding and utilizing TNF-α inhibition for the treatment of psoriatic arthritis.

Caso F, Lubrano E, Del Puente A, Caso P, Peluso R, Foglia F, Benigno C, Girolimetto N, Bottiglieri P, Scarpa R, Costa L.

Expert Rev Clin Immunol. 2016 Mar;12(3):315-31. doi: 10.1586/1744666X.2016.1117941. Epub 2015 Dec 9.

PMID:
26558483
14.

Role of Agents other than Tumor Necrosis Factor Blockers in the Treatment of Psoriatic Arthritis.

Atzeni F, Costa L, Caso F, Scarpa R, Sarzi-Puttini P.

J Rheumatol Suppl. 2015 Nov;93:79-81. doi: 10.3899/jrheum.150643.

PMID:
26523064
15.

Ex Vivo Signaling Protein Mapping in T Lymphocytes in the Psoriatic Arthritis Joints.

Fiocco U, Martini V, Accordi B, Caso F, Costa L, Oliviero F, Scanu A, Felicetti M, Frallonardo P, Facco M, Boso D, Molena B, Zambello R, Ramonda R, Cozzi F, Scarpa R, Basso G, Semenzato G, Dayer JM, Doria A, Punzi L.

J Rheumatol Suppl. 2015 Nov;93:48-52. doi: 10.3899/jrheum.150636.

PMID:
26523057
16.

The Definition and Measurement of Axial Psoriatic Arthritis.

Lubrano E, Parsons WJ, Marchesoni A, Olivieri I, D'Angelo S, Cauli A, Caso F, Costa L, Scarpa R, Brunese L.

J Rheumatol Suppl. 2015 Nov;93:40-2. doi: 10.3899/jrheum.150634.

PMID:
26523055
17.

Fragility Fractures in Patients with Psoriatic Arthritis.

Del Puente A, Esposito A, Costa L, Benigno C, Del Puente A, Foglia F, Oriente A, Bottiglieri P, Caso F, Scarpa R.

J Rheumatol Suppl. 2015 Nov;93:36-9. doi: 10.3899/jrheum.150633.

PMID:
26523054
18.

Psoriatic Disease: Clinical Staging.

Scarpa R, Caso F, Costa L, Peluso R, Spanò A, Lubrano E, Del Puente A, Moll JM.

J Rheumatol Suppl. 2015 Nov;93:24-6. doi: 10.3899/jrheum.150629.

PMID:
26523050
19.

Third Update on Psoriatic Disease Conference: Trainee Session.

Moll JM, Scarpa R.

J Rheumatol Suppl. 2015 Nov;93:6-9. doi: 10.3899/jrheum.150623.

PMID:
26523045
20.

PHYSIOPATHOLOGY OF OSTEOPOROSIS: FROM RISK FACTORS ANALYSIS TO TREATMENT.

Del Puente A, Esposito A, Del Puente A, Costa L, Caso F, Scarpa R.

J Biol Regul Homeost Agents. 2015 Jul-Sep;29(3):527-31. Review.

PMID:
26403391
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk